Tag Archives: Small Times Magazine

Sep. 16, 2005 – When Neil Wyant was a kid growing up in Akron, Ohio, he says he cut out from school for brief periods to buy a bulk piece of chewing gum. Back in class, he would break it up into bite-size pieces and sell it at a comfortable markup.

So it was no surprise to family and friends that the Chicago-based entrepreneur is back to hawking gum, only this time it is of the micro-enhanced, patent-pending, chocolate kind.

“This has been described by a couple of people as sort of the holy grail of chewing gum,” said Wyant, president of O’lala Foods. Veterans like Wm. Wrigley Jr. Co. had declared that the cocoa butter in chocolate makes the gum base too mushy.

But Wyant and partner Michael Gurn say they found a solution. They use a proprietary microencapsulation process that Gurn invented that combines the taste of chocolate powder with the creamy texture that people expect in a chocolate product. The partners, who also are distant cousins, sell their Choco’la gourmet chocolate gum across the country for between $1.29 and $3.

The cousins are arguably the best combination since, well, chocolate and peanut butter: Gurn is an independent inventor and Wyant was the licensing director for Argonne National Laboratory. Today they have what Wyant characterizes as a portfolio of food technologies supported by methods and materials claims as well as a pipeline of a dozen new products.

“We know the gum is always going to be a niche product,” Wyant admitted. But it serves as a proof of concept, attracts lots of attention and generates early revenues. Other improvements to basic foods could include skim milk that tastes like regular milk, candy bars with better nutritional content and diet chocolate.

To be fair, says Wyant, the Food and Drug Administration has a strict definition of “chocolate” that his product doesn’t technically meet because it lacks the requisite amount of cocoa butter. But, he says, customers don’t seem to mind.

Next up is hazelnut cappuccino gum. Now that’s an idea worth chewing on.

Sep. 15, 2005 — NanoOpto Corp., A Somerset, N.J., company that is applying novel design methods and proprietary nanofabrication technology to produce a broad range of optical components, announced that Nada O’Brien has joined the company as vice president of product development.

Prior to joining NanoOpto, O’Brien was product development manager at JDS Uniphase, where she was responsible for the launch of new products in a $40 million global optics and display business.

Sep. 14, 2005 – Arrowhead Research Corp. (Nasdaq:ARWR) announced the appointment of Virginia Dadey as vice president of investor relations. Dadey has fifteen years of experience in financial markets as an investment specialist and will function as Arrowhead’s investor point person. She will be based in New York City, where she is expected to build Arrowhead’s shareholder base and improve shareholder liquidity.

Dadey previously worked for the Maxim Group as senior vice president for institutional sales. Prior to working for Maxim, she was a vice president at Gruntal & Co. from 1996 to 2001.

Sep. 13, 2005 — Brooks Automation Inc., a maker of products to enable manufacturing efficiencies for the semiconductor and other industries, and Surface Technology Systems PLC (STS), a provider of specialized plasma etch and deposition systems, announced that STS will be introducing new etch systems utilizing Brooks’ Marathon Express family of vacuum cluster tool automation platforms.

STS offers a range of products for semiconductor device manufacturing process applications such as advanced silicon etch, advanced oxide etch, inductively coupled plasma etch, reactive ion etch, chemical vapor etch, and plasma enhanced chemical vapor deposition.

The Brooks vacuum automation platform is an important enabler for STS, according to a prepared statement by Leslie Lea, deputy chief executive officer and chief technical officer at STS, who said that it allows the company to focus its R&D investments more efficiently on its core process technologies.

Sep. 12, 2005 – The Global Emerging Technology Institute will sponsor a research and commercialization mission to mainland China and Hong Kong in October in order to understand efforts to support cutting edge, applied micro and nanotechnology R&D activities, commercialization efforts and their potential impact on growing technology sectors.

The intent of the mission is to canvass the leading research centers of China and review commercialization efforts taking place for new enabling micro and nanotechnologies. Micro- and nanotechnology experts from the U.S. and China are slated to lead the mission, with corporate representatives from the U.S., Europe and Japan expected to attend.

Source: INSEAD InnovAsia

Sep. 9, 2005 – Novavax Inc. announced the appointment of Robert Lee to the position of vice president of pharmaceutical development. Lee will report directly to Rahul Singhvi, president and CEO.

Lee, 45, joins Novavax following 15 years in pharma research and development of therapeutic drugs and diagnostic imaging agents. Most recently he was vice president of product development for Lyotropic Therapeutics Inc. in Ashland, Va.

From 1990 to 2002, Lee held various research & development positions with Sterling Winthrop Pharmaceuticals, NanoSystems, and elan Drug Delivery Inc. His areas of expertise include preformulation, drug delivery, formulation development, analytical sciences, sterile manufacturing, and technology evaluation and development. He was one of the founders of NanoSystems.

Novavax is attempting to develop products using a proprietary micellar nanoparticle technology.

By Candace Stuart

Sep. 9, 2005 – Public awareness of nanotechnology hovers in the angstrom range today, but that’s likely to change as nanotech’s potential translates into more products. That doesn’t automatically mean people will buy in, though.

Knowing how an informed public views nanotechnology, and how an uninformed public forms its opinions, could help pave the way toward acceptance. In two separate studies on public perceptions of nanotechnology, researchers warn that winning the public’s support will require more open engagement from industry, government and scientists.

“There are two things people are asking for,” said David Rejeski, director of the Project on Emerging Nanotechnologies. The project unveiled its study, “Informed public perceptions of nanotechnology and trust in government,” on Thursday. “They want more information; they feel they are in the dark and neither government nor industry provides information. And they want more testing on environment and health (effects).”

Jane Macoubrie, the project’s senior adviser and a social scientist specializing in communications, conducted the study in May and June using 177 participants from Dallas, Cleveland and Spokane, Wash. Participants were given a pre-test questionnaire about nanotechnology and then provided written material about nanotechnology, regulatory and policy groups associated with nanotechnology, and consumer and biotech applications and products.

Participants read the material before joining in individual and group discussions as well as taking a post-test questionnaire. The study was prompted by earlier research that found low levels in trust in government’s ability to manage nanotechnology’s risks. The 2005 study was meant to better understand why trust was low and with which agencies, and to get a read on public attitudes and concerns.

“Based in their experiences, people have concerns about products that predate nanotechnology, but may be reinforced by nanotechnology,” Macoubrie said. Many participants mentioned Vioxx as an example of government and industry’s failure to protect consumers. Merck withdrew the painkiller from the market after the drug was linked to heart attacks and strokes.

Most participants believed self-regulation by the nanotech industry would not be sufficient, and more than half recommended some type of government control.

Trust in Congress’ ability to manage risk remained low in pre- and post-tests, with 63 percent of post-test respondents giving lawmakers a no-confidence vote. Some regulatory agencies edged up in post-tests, but groups that have been associated with debacles such as the Food and Drug Administration, which approved Vioxx, faired poorly.

Public trust would increase if government and industry increased the amount of testing before products went to market, the study found. More than 70 percent of participants called for more pre-launch testing, more information about choices and proof that regulations protected workers and the environment.

“Here’s an opportunity for industry to try to get it right,” Macoubrie said. Rejeski suggested that third-party testing and industry collaborations with a trusted party such as a university would also boost pubic confidence. He recommended finding mechanisms to engage the public in national policy decisions.

Public policy tends to be made in government,” he said. “The public can help solve some of these tricky policy problems.”

Macoubrie also encouraged industry to heed the public’s message. “We need to think about what the public is saying and what that means for the nanotechnology industry globally,” she added. “We need to close this gap, and take this gap seriously, between where the public thinks we are and where industry would like to be.”

Another study scheduled to be published in the Journal of Nanoparticle Research discusses how an uninformed public generally will get information and draw conclusions about nanotechnology.

Dietram Scheufele, a professor of journalism and mass communication at the University of Wisconsin-Madison, predicts most people will not invest the time and effort to understand nanotechnology. Instead they will be “cognitive misers” who collect as little information as needed and use shortcuts such as media portrayals to form opinions.

“This is how they make judgments,” Scheufele said. “They will still make policy decision, based on how nanotechnology is being covered. This makes sense; it’s not that relevant for them. ¿We’re all misers in certain areas and non-misers in others.”

In the paper, “The public and nanotechnology: How citizens make sense of emerging technologies,” Scheufele and co-author Bruce Lewenstein of Cornell University found that in a survey of more than 700 people, about 16 percent were somewhat informed about nanotechnology. About 59 percent of the informed group said they supported nanotechnology, while only 28 percent of unaware group expressed support.

Nanotechnology stories today often appear in business and science sections or magazines, which tend to put nanotech in a positive light, according to Scheufele. The researchers argue that nanotechnology as a topic soon will migrate to the more mainstream press. The less specialized press likely will present the story in terms of a controversy, with issues framed by dueling interests that disregard scientific information.

But that is not inevitable, Scheufele said. Scientists can position themselves in this early, non-controversial stage to ensure their voices are heard in later dialogues.

“The key to successful communication about nanotechnology will be scientists,” he said. “Scientists can take a proactive role in participating in public discourse” by establishing media contacts and building a reputation as a reliable source.

Scientific reasoning may then become part of the framework that the public will use to make its decisions. In the end, Scheufele said, they still may choose against nanotechnology but the decision will be more informed.

“The outcome is less important than the process,” he said. “I want the debate to take place with all parties.”

Editor’s note: The Woodrow Wilson International Center for Scholars and Pew Charitable Trusts have partnered on the Project on Emerging Nanotechnologies. The project’s study is available online at www.wilsoncenter.org.

Sep. 8, 2005 — Applied Biosystems (NYSE:ABI), an Applera Corp. business, announced the commercial release of its TaqMan microRNA assays for the detection and quantitation of mature human microRNA expression levels.

MicroRNAs are a recently discovered class of small RNA molecules known to play a regulatory role in cell differentiation, developmental biology, and diseases such as cancer.

Catherine Burzik, president of Applied Biosystems, said in a prepared statement that the assays can eliminate major challenges in detecting and quantifying miRNAs and are expected to stimulate research in areas such as cancer, stem cell research, and developmental biology.

Several early access partners presented research results using a preliminary version of the assays. In May 2005, Dartmouth University presented findings at the European Society of Human Genetics Annual Meeting demonstrating the ability of the assays to reveal miRNA expression changes in an aggressive form of brain cancer.

Sep. 7, 2005 – Altium Ltd. (ASX: ALU), a developer of Windows-based electronics design software, announced the selection of Altium Designer as the electronics design system of choice by Agilent Technologies‘ strategic new joint venture in China, Agilent-Qianfeng Electronics Technologies.

A short learning curve, ease of operation, tight integration and cost effectiveness played into the decision, according to a prepared statement by Xiaofei Ma, general manager of R&D at Aglient-Qianfeng.

Formed in January 2005, Agilent-Qianfeng Electronics Technologies is a joint venture between Agilent Technologies’ test and measurement organization and Chengdu Qianfeng Electronics Ltd, and is responsible for the development and manufacturing of test equipment for the Chinese and world markets. The new joint venture is a key component of Agilent Technologies’ involvement in China’s rapidly-growing electronics industry. Chengdu Qianfeng is in electronic equipment, household appliances and electronic machinery.

Sep. 7, 2005 — Accent Optical Technologies, a supplier of lattice engineering and photolithography process control tools, announced that the Korean Advanced Nano Fab Center has ordered a suite of Accent metrology tools.

The tools are slated to be used in the development of advanced materials for use in nanoscale electronic and optical devices. The order includes an RPM Photoluminescence mapping tool, an ECVpro electrochemical CV profiler and a Hall Effect measurement system.

The Korean Advanced Nano Fab Center was established in late 2003 with the mission to enhance Korean competitiveness in nanotechnology and contribute to the development of relevant industries by constructing an R&D support system in the field of non-silicon-based nano devices. Its partners include Samsung and LG, as well as leading Korean Universities.

The center is intended to provide facilities for the development of nano-electronic and photonic devices and hybrid compound semiconductor devices, as well as support basic research in the emerging fields of nanotubes, molecular devices and spintronics.